Neurocrine is committed to transparency in its interactions. Neurocrine commits to following relevant pharmaceutical codes and has published details of its transfers of value below. Where individual countries have other transparency regulations, Neurocrine's declarations for these can be found in the Transparency dropdown menu on a country-specific basis. Disclosures prior to 2025 are reported under the legacy name Diurnal.